Inclusion of Obese Participants in Drug Development: Reflections on the Current Landscape and a Call for Action
Authors:
- Kenneth T. MooreKMKenneth T. Moore
- Karthik VenkatakrishnanKVKarthik Venkatakrishnan
- the ACCP Public Policy CommitteeTCthe ACCP Public Policy Committee
- 13 November 2023
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 64 (1) , 13-18
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parametersExpert Opinion on Drug Metabolism & Toxicology, 2018
- American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with ObesityEndocrine Practice, 2016
- Drug Disposition in Obesity: Toward Evidence-Based DosingAnnual Review of Pharmacology and Toxicology, 2015
- 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in AdultsCirculation, 2014
- Drug Dosing Based on Weight and Body Surface Area: Mathematical Assumptions and Limitations in Obese AdultsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012
- Impact of Obesity on Drug Metabolism and Elimination in Adults and ChildrenClinical Pharmacokinetics, 2012
- Bariatric Surgery-Induced Weight Loss Reduces Hepatic Lipid Peroxidation Levels and Affects Hepatic Cytochrome P-450 Protein ContentAnnals of Surgery, 2010
- Effects of Obesity on PharmacokineticsClinical Pharmacokinetics, 2000
- Pharmacokinetics and pharmacodynamics of methylprednisolone in obesityClinical Pharmacology & Therapeutics, 1991
- Prolonged Accumulation of Diazepam in ObesityThe Journal of Clinical Pharmacology, 1983